Anocca

Anocca

Forskning inom bioteknik

Engineered Immunity

Om oss

Anocca understands the complexity of T-cell biology. We have established a unique technology platform that replicates functional human cellular immunobiology and unlocks the potential of T-cell immunotherapies and vaccine strategies that leverage T-cell immunity. Anocca’s approach and proprietary technologies deliver the means to efficiently and precisely harness and manipulate T-cell immunity, enabling a range of next-generation therapies and vaccination strategies that address unmet patient need in oncology, infectious disease and autoimmunity. Today Anocca has a focus on delivering T-cell receptor-modified T-cell therapies (TCR-T) in oncology. Anocca is rapidly progressing a pipeline of novel therapeutic TCR-T candidates generated entirely with our own technologies towards clinical trials utilising our in-house state-of-the-art manufacturing capabilities and processes.

Bransch
Forskning inom bioteknik
Företagsstorlek
51–200 anställda
Huvudkontor
Södertälje
Typ
Privatägt företag
Grundat
2014
Specialistområden
Biotechnology, Immunotherapeutics, Drug Discovery, Drug Development, Immunology, Immunotechnology och Immuno-Oncology

Adresser

Anställda på Anocca

Uppdateringar

Liknande sidor

Finansiering

Anocca 3 rundor totalt

Senaste finansieringsrunda

Okänd serie

36 891 357,00 US$

Se mer info på crunchbase